Talecris tests IPO waters
This article was originally published in Scrip
Executive Summary
Talecris Biotherapeutics is the latest company to test the IPO market with plans to raise more than $500 million. The US firm will be only the second drug company to float on Nasdaq in nearly two years if the offering succeeds.